FINHUB Insights

MCK · Q3 FY25 · Oct 1 – Dec 31, 2024

McKesson Q3 FY25: where the revenue came from and where it went

McKesson Q3 FY25: revenue $95.3B (+18% year over year). Net profit $0.9B. Largest cohort U.S. Pharmaceutical $87.1B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2024
Reported
Feb 6, 2025 10-Q
Sankey diagram of McKesson's income statement for Q3 FY25: revenue of $95.3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$95.3B +18% year over year
Gross profit$3.3B 3% margin
Operating profit$1.2B 1% margin
Net profit$0.9B 1% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Dec 31, 2024).
ItemValueShare of revenueYear over year
Revenue 95.3 100% +18%
U.S. Pharmaceutical 87.1 91%
International 3.9 4%
Medical-Surgical Solutions 2.9 3%
Prescription Technology 1.4 1%
Cost of revenue−9297%
Gross profit3.33% margin+0pp
SG&A−2.12%−1pp
Operating profit1.21% margin+0pp
Tax−0.3
Net profit0.91%+0pp
Filing on EDGAR More quarters of MCK

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters